<DOC>
	<DOCNO>NCT00309231</DOCNO>
	<brief_summary>The purpose study perform series islet transplant use Edmonton protocol . Patients Type I Diabetes glycemic lability , severe hypoglycemia hypoglycemic unawareness undergo transplantation purify pancreatic islet cadaveric donor portal vein , follow steroid-free immunosuppression per Edmonton protocol ( IL-2 antibody induction , sirolimus , low dose tacrolimus-based immunosuppression ) . The goal transplant improve glycemic control , stabilize blood sugar achieve insulin independence .</brief_summary>
	<brief_title>Clinical Islet Transplantation Using Edmonton Protocol</brief_title>
	<detailed_description>The purpose study document outcome islet transplant centre replicate Edmonton protocol . The Edmonton protocol , describe , currently standard clinical protocol conduct clinical islet transplantation select patient type 1 diabetes . We propose conduct feasibility study document availability frequency donor organ , test process islet isolation , assess implementation procedure transplant islet administer immunosuppression , monitor complication immunosuppression document success safety transplant procedure centre . The outcome propose document include : 1 ) number patient achieve insulin independence one year complete Edmonton protocol 2 ) A1c value one year complete Edmonton protocol 3 ) graft survival measure basal stimulate C-peptide level 4 ) islet equivalent isolate donor organ islet equivalent per kg transplant 5 ) complication islet transplant immunosuppressive therapy . Eight patient type 1 diabetes 5 year undergo islet allotransplantation use Edmonton protocol . It expect patient require minimum two transplant procedure receive enough islet achieve insulin independence . Procedures follow publish guideline . Pancreata isolate brain-dead donor accord publish protocol , include two-layer cold storage method . Islets culture 48 hour facilitate time islet infusion . Islets infuse portal vein . Post transplant immunosuppression consist modify Edmonton protocol outline Ryan et al include basiliximab induction therapy , sirolimus tacrolimus maintenance therapy , aspirin enoxaparin thromboprophylaxis , pneumocystis carinii prophylaxis sulfamethoxazole/trimethoprim 6 month cytomegalovirus prophylaxis 3 month indicate . Insulin requirement monitor closely transplant . Serum glucose , glycosylated haemoglobin , serum C-peptide , creatinine , lipid concentration monitor . Patients see follow every month initially long term every 3 6 month require . Glucose control , immunosuppressive level adverse event monitor regularly . Patients monitor complication diabetes per standard guideline . Tests beta cell function ( mixed meal Ensure test glucose C-peptide ) perform every 3 month initially every 6 month stable .</detailed_description>
	<criteria>age 1865 year type 1 diabetes least 5 year least 1 follow : ) frequent , severe hypoglycaemia b ) hypoglycemic unawareness* c ) glycemic lability despite optimal insulin regimen* , failure intensive insulin therapy judge independent endocrinologist obesity ( BMI &gt; 28 insulin requirement &gt; 0.7 U/kg/day history cancer ( except basal squamous skin cancer ) unstable , severe , noncorrectable cardiac disease previous organ transplant evidence sensitization ( PRA &gt; 20 % ) renal dysfunction ( macroalbuminuria , renal dialysis ) untreated proliferative retinopathy active infection , include hep C , hep B , HIV , TB current cigarette smoking ( 6 month abstinence require ) substance abuse indication steroid medication ( exception steroid inhaler , topical steroid ) indication anticoagulation ( exception aspirin ) pregnancy desire future pregnancy ; breastfeed major psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>islet transplantation</keyword>
</DOC>